Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
- Conditions
- Acute Undifferentiated LeukemiaAcute Leukemia of Ambiguous LineageMixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise SpecifiedMixed Phenotype Acute LeukemiaMixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise SpecifiedAcute Bilineal LeukemiaAcute Biphenotypic LeukemiaRecurrent Mixed Phenotype Acute Leukemia
- Interventions
- First Posted Date
- 2014-05-12
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT02135874
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
- Conditions
- Interventions
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2021-02-15
- Lead Sponsor
- Zhejiang University
- Registration Number
- NCT02129322
- Locations
- 🇨🇳
First affiliated hospital, Zhejiang University, Hangzhou, China
Second Line Sorafenib After Pazopanib in Patients With RCC
- First Posted Date
- 2014-04-24
- Last Posted Date
- 2017-11-22
- Target Recruit Count
- 16
- Registration Number
- NCT02122003
- Locations
- 🇮🇹
Istituto Tumori, Milan, Mi, Italy
Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study
- First Posted Date
- 2014-03-12
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Instituto Nacional de Cancerologia, Columbia
- Target Recruit Count
- 35
- Registration Number
- NCT02084732
- Locations
- 🇨🇴
Instituto Nacional de Cancerología, Bogotá, Cundinamarca, Colombia
Sorafenib for Hepatopulmonary Syndrome
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 28
- Registration Number
- NCT02021929
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸University of Texas Health Science Center at Houston Medical School, Houston, Texas, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT02015728
- Locations
- 🇺🇸
Seattle Children's, Seattle, Washington, United States
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-11-20
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 117
- Registration Number
- NCT01988493
- Locations
- 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
🇰🇷National Cancer Center, Goyang-si, Korea, Republic of
🇨🇳Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT01946529
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma
- First Posted Date
- 2013-08-30
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT01932385
- Locations
- 🇨🇳
Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China
Sorafenib Chemoembolization Evaluation Controlled Trial
- First Posted Date
- 2013-07-24
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Air Force Military Medical University, China
- Target Recruit Count
- 199
- Registration Number
- NCT01906216
- Locations
- 🇨🇳
Xijing Hospital of Digestive Disease, Xi'an, Shaanxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.